On March 20, 2018 Crescendo Biologics Limited (Crescendo), the drug developer of novel,targeted T-cell engaging therapeutics, reported Dr Brian McGuinness, Head of New Product andBusiness Development, Phil Bland-Ward (CSO) and James Legg (VP R&D) will be presenting a poster at AACR (Free AACR Whitepaper) (American Association for Cancer Research) Annual Meeting in Chicago, USA on 18 April 2018 (Press release, Crescendo Biologics, MAR 20, 2018, View Source [SID1234525091]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Crescendo team will be available to discuss the poster entitled "Multifunctional biologics fortargeted T-cell therapy based on in vivo matured fully human VH domains" within the "Antibodies,Fusion Proteins and Related Biologics session". This will cover the beneficial characteristics of Humabodies and their enhanced therapeutic potential over traditional monoclonal antibodies.

Poster details
Title: Multifunctional biologics for targeted T-cell therapy based on in vivo matured fully human VHdomains
Authors: J. Legg, B. McGuinness, P. Bland-Ward, P. Pack
Session Category: Experimental and Molecular Therapeutics
Session Title: Antibodies, Fusion Proteins, and Related BiologicsSession Date and Time: Wednesday Apr 18, 2018 8:00 AM – 12:00 PM
Location: McCormick Place South, Exhibit Hall A, Poster Section 35

Poster Board Number: 11
Permanent Abstract Number: 5766

There will also be a poster by Eleven Biotherapeutics in the same session which includes data fromCrescendo. This poster, entitled ‘Engineering and characterization of anti-PSMA humabody-deBouganinfusion proteins’, will be at Board Number 15.

AACR’s Annual Meeting is being held in Chicago, Illinois from 14 – 18 April. The theme is ‘DrivingInnovative Cancer Science to Patient Care’. Presentations at the Annual Meeting will cover the latestbasic, translational, clinical, and prevention-focused research in the field, including important areas suchas early detection, cancer interception, and survivorship in all populations.

On March 20, 2018 Johnson & Johnson (NYSE: JNJ) reported that it will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, April 17, to review first-quarter results. Dominic Caruso, Executive Vice President, Chief Financial Officer; Joaquin Duato, Executive Vice President, Worldwide Chairman, Pharmaceuticals and Joseph J. Wolk, Vice President, Investor Relations, will host the call (Press release, Johnson & Johnson, MAR 20, 2018, View Source [SID1234524910]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investors and other interested parties can access the webcast/conference call in the following ways:

The webcast and presentation material are accessible at Johnson & Johnson’s website www.investor.jnj.com. A replay of the webcast will be available approximately three hours after the conference call concludes.
By telephone: for both "listen-only" participants and those financial analysts who wish to take part in the question-and-answer portion of the call, the telephone dial-in number in the U.S. is 877-869-3847. For participants outside the U.S., the dial-in number is 201-689-8261.
A replay of the conference call will be available until approximately 12:00 a.m. on April 25, 2018. The replay dial-in number for U.S. participants is 877-660-6853. For participants outside the U.S., the replay dial-in number is 201-612-7415. The replay conference ID number for all callers is 13677626.
The press release will be available at approximately 6:45 a.m. (Eastern Time) the morning of the conference call.

AC Immune has filed a 20-F – Annual and transition report of foreign private issuers [Sections 13 or 15(d)] with the U.S. Securities and Exchange Commission (Filing, 20-F, AC Immune, 2018, MAR 20, 2018, View Source [SID1234526042]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On March 19, 2018 – Diplomat Pharmacy Inc. (NYSE: DPLO)reported that it will participate in Needham & Company’s 17th annual healthcare conference in New York City (Press release, Diplomat Speciality Pharmacy, MAR 19, 2018, View Source;Company-Healthcare-Conference/default.aspx [SID1234524887]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Diplomat Specialty Pharmacy (PRNewsFoto/Diplomat Pharmacy, Inc.)

Interim CEO Jeff Park and Chief Financial Officer Atul Kavthekar are scheduled to present at 11:30 a.m. ET Wednesday, March 28.

Live audio-only webcasts of the presentation and related materials will be available on the investor relations section of Diplomat’s website at ir.diplomat.is. The webcast and presentation materials will be online for 90 days.

On March 14, 2018 Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, reported its presented promising clinical data from the study evaluating DKN-01, Leap’s anti-DKK1 monoclonal antibody, as a monotherapy in patients with advanced esophagogastric cancer (Press release, Leap Therapeutics, MAR 19, 2018, View Source [SID1234524889]). In addition, Leap announced that the first patient has been enrolled in the study evaluating DKN-01 in patients with gynecological cancers. Leap also announced two upcoming scientific presentations at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) 2018 Annual Meeting.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

DKN-01 Monotherapy in Patients with Esophagogastric Cancer
Data presented today at the Barclays Global Healthcare Conference included 16 patients with advanced esophagogastric cancer who were treated with DKN-01 monotherapy. Central imaging review identified two patients (12.5%) with a best response of a partial response and five patients (31.3%) with stable disease, representing a total disease control rate of 43.8%. This cohort of patients had received many different lines of prior therapy. One patient who had failed prior investigational immunotherapies, including a PD-L1 antagonist and IDO inhibitor, had a partial response on DKN-01 monotherapy and remained on study for over a year.

"The results of the DKN-01 monotherapy cohort demonstrate promising single agent activity in a very difficult to treat population of heterogeneous esophagogastric cancer. This data, in addition to the encouraging activity we have seen with DKN-01 in preclinical models and in patients in combination with chemotherapy, provides a strong foundation for our ongoing study in combination with the anti-PD-1 therapy Keytruda," commented Cynthia Sirard, MD, Vice President of Clinical Development for Leap.

DKN-01 Gynecologic Malignancies Study

Leap also announced that the first patient has been dosed in a Phase 2 clinical trial evaluating DKN-01 as a monotherapy and in combination with paclitaxel chemotherapy in patients with advanced endometrioid gynecologic malignancies. The study is part of Leap’s strategy to treat cancer patients with documented mutations of the Wnt signaling pathway, a biomarker identified in patients who have responded to DKN-01 therapy. Data presented today by Leap demonstrates that uterine cancer patients with these mutations often have elevated intratumoral levels of DKK1.

"Mutations of the Wnt pathway, particularly beta-catenin, are highly prevalent in endometrioid gynecologic cancers, and often thought to be a driver of an aggressive subgroup of the disease," commented Michael Birrer, M.D., Ph.D., Director of the Comprehensive Cancer Center at the University of Alabama at Birmingham and an investigator on the study. "We are excited to begin this trial of DKN-01, which has shown promising activity in patients with Wnt signaling mutations in other solid tumor malignancies."

The study is a Phase 2 basket study evaluating DKN-01 as a monotherapy and in combination with paclitaxel in patients with relapsed/refractory endometrioid endometrial cancer (EEC) or endometrioid ovarian cancer (EOC). The study contains four groups and is designed to evaluate the efficacy, safety, and pharmacodynamics of DKN-01 monotherapy and combination therapy in both EEC and EOC, with each group following a 2-stage Simon Minimax design. The study will enroll approximately 94 patients, of which ~ 50% will be required to have documented activating mutations of beta-catenin or other Wnt signaling alterations.

Upcoming Presentation at AACR (Free AACR Whitepaper) Annual Meeting
Additionally, Leap announced two poster session presentations at the AACR (Free AACR Whitepaper) Annual Meeting, being held April 14 – 18, 2018, in Chicago, IL.

Abstract Number and Title: 1710 / 5 – DKN-01, a therapeutic DKK1 neutralizing antibody, has immune modulatory activity in nonclinical tumor models

Session Title: Immune Response to Therapies 2

Session Date and Time: April 16, 2018, 8:00 AM – 12:00 PM

Session Location: McCormick Place, Poster Section 32

Abstract Number and Title: 1699 / 24 – Treatment with agonist anti-GITR antibody after chemotherapy enhances tumor immunity

Session Title: Immune Checkpoints 1

Session Date and Time: April 16, 2018, 8:00 AM – 12:00 PM

Session Location: McCormick Place, Poster Section 31